Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 642

1.

Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy.

Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Oncol Rep. 2010 May;23(5):1213-20.

PMID:
20372832
[PubMed - indexed for MEDLINE]
2.

Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.

Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Tumori. 2010 Jan-Feb;96(1):103-10.

PMID:
20437866
[PubMed - indexed for MEDLINE]
3.

Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.

Vargo JA, Beriwal S, Ahrendt GM, Soran A, Johnson RR, McGuire K, Bhargava R.

Oncology. 2011;80(5-6):341-9. doi: 10.1159/000330203. Epub 2011 Jul 26.

PMID:
21791944
[PubMed - indexed for MEDLINE]
4.

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S.

J Clin Oncol. 2012 May 20;30(15):1796-804. doi: 10.1200/JCO.2011.38.8595. Epub 2012 Apr 16.

PMID:
22508812
[PubMed - indexed for MEDLINE]
5.

Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.

De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES.

Cancer. 2013 May 15;119(10):1776-83. doi: 10.1002/cncr.27995. Epub 2013 Feb 21.

PMID:
23436342
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.

Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE.

J Natl Cancer Inst. 2012 Mar 7;104(5):406-14. doi: 10.1093/jnci/djr543. Epub 2012 Jan 16.

PMID:
22250182
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.

Clin Cancer Res. 2007 Apr 15;13(8):2329-34.

PMID:
17438091
[PubMed - indexed for MEDLINE]
Free Article
8.

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.

von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M; German Breast Group.

Breast Cancer Res. 2008;10(2):R30. doi: 10.1186/bcr1989. Epub 2008 Apr 1.

PMID:
18380893
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.

Jeong JH, Jung SY, Park IH, Lee KS, Kang HS, Kim SW, Kwon Y, Kim EA, Ko KL, Nam BH, Lee S, Ro J.

Invest New Drugs. 2012 Feb;30(1):408-16. doi: 10.1007/s10637-010-9555-7. Epub 2010 Oct 5.

PMID:
20922557
[PubMed - indexed for MEDLINE]
10.

The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.

Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C, Navarro-Perez V, Alba-Conejo E, Sánchez-Rovira P.

Clin Breast Cancer. 2013 Apr;13(2):146-52. doi: 10.1016/j.clbc.2012.11.006. Epub 2013 Jan 11.

PMID:
23318089
[PubMed - indexed for MEDLINE]
11.

Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.

Cortesi L, De Matteis E, Cirilli C, Marcheselli L, Proietto M, Federico M.

Tumori. 2012 Nov;98(6):743-50. doi: 10.1700/1217.13498.

PMID:
23389361
[PubMed - indexed for MEDLINE]
12.

Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.

Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E.

Eur J Cancer. 2012 Dec;48(18):3342-54. doi: 10.1016/j.ejca.2012.05.023. Epub 2012 Jul 3.

PMID:
22766518
[PubMed - indexed for MEDLINE]
13.

Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.

Matsubara N, Mukai H, Fujii S, Wada N.

Breast Cancer Res Treat. 2013 Jan;137(1):203-12. doi: 10.1007/s10549-012-2344-6. Epub 2012 Nov 27.

PMID:
23184081
[PubMed - indexed for MEDLINE]
14.

Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer.

Li J, Liu X, Tong Z.

Jpn J Clin Oncol. 2012 Jun;42(6):471-6. doi: 10.1093/jjco/hys046. Epub 2012 Apr 3.

PMID:
22493058
[PubMed - indexed for MEDLINE]
Free Article
15.

Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.

Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J; Danish Breast Cancer Cooperative Group.

J Clin Oncol. 2008 Mar 20;26(9):1419-26. doi: 10.1200/JCO.2007.14.5565. Epub 2008 Feb 19.

PMID:
18285604
[PubMed - indexed for MEDLINE]
16.

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.

Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, Katsumata N, Kinoshita T, Takiguchi Y, Tanzawa H, Fujiwara Y.

Breast Cancer Res Treat. 2012 Apr;132(3):793-805. doi: 10.1007/s10549-011-1554-7. Epub 2011 May 12.

PMID:
21562709
[PubMed - indexed for MEDLINE]
17.

Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.

Petit T, Wilt M, Velten M, Rodier JF, Fricker JP, Dufour P, Ghnassia JP.

Breast Cancer Res Treat. 2010 Nov;124(2):387-91. doi: 10.1007/s10549-010-1142-2. Epub 2010 Sep 8.

PMID:
20824324
[PubMed - indexed for MEDLINE]
18.

Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.

Abdulkarim BS, Cuartero J, Hanson J, Deschênes J, Lesniak D, Sabri S.

J Clin Oncol. 2011 Jul 20;29(21):2852-8. doi: 10.1200/JCO.2010.33.4714. Epub 2011 Jun 13.

PMID:
21670451
[PubMed - indexed for MEDLINE]
19.

The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.

Gabos Z, Thoms J, Ghosh S, Hanson J, Deschênes J, Sabri S, Abdulkarim B.

Breast Cancer Res Treat. 2010 Nov;124(1):187-94. doi: 10.1007/s10549-010-1135-1. Epub 2010 Sep 3.

PMID:
20814819
[PubMed - indexed for MEDLINE]
20.

Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.

Precht LM, Lowe KA, Atwood M, Beatty JD.

Breast J. 2010 Jul-Aug;16(4):362-8. doi: 10.1111/j.1524-4741.2010.00935.x. Epub 2010 Apr 28.

PMID:
20443786
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk